Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.

摘要: Background: With the exception of alanine aminotransferase (ALT) level, baseline factors predictive therapeutic response to lamivudine in patients with hepatitis B e antigen (HBeAg)-positive chronic (CHB) remain unknown. We thus studied influence pre-therapy viral on end-of-treatment responses lamivudine. Methods: A total 116 treatment-naive HBeAg-positive CHB who had ALT level >5x upper limit normal (ULN) and received for 12-18 months were enrolled. HBeAg seroclearance combined seroclearance, normalization undetectable virus DNA at end therapy defined as primary secondary endpoints, respectively. Pre-therapy including load, genotype, precore (PC) stop codon status, basal core promoter status pre-S deletion determined correlate endpoints. Results: The frequency detectable PC mutation (G1896A), (A1762T/G1764A) was 22.4%, 21.6% 12.1%, After therapy, overall rate 56.0%. Patients a higher prevalence than those without (30.8% versus 11.8%; P=0.015). By using multivariate analyses, odds ratio develop 3.33 (P=0.024). presence also correlated response. Conclusions: For lamivudine-treated levels >5xULN, could predict therapy.